Related Experiment Video
Updated: Sep 28, 2025

Isolation of Pulmonary Artery Smooth Muscle Cells from Neonatal Mice
Published on: October 19, 2013
Extremely premature infants born at 23-25 weeks gestation are at substantial risk for pulmonary hypertension
Hannes Sallmon1,2,3, Martin Koestenberger4,5, Alexander Avian6
1Department of Pediatric Cardiology, Charité-Universitätsmedizin Berlin, Berlin, Germany. sallmon@dhzb.de.
Insights
Pulmonary hypertension associated with bronchopulmonary dysplasia (BPD-PH) affects 44% of extremely low gestational age newborns (ELGANs). Pharmacotherapy improved hemodynamics in most infants by 12 months.
Area of Science:
- Neonatal Medicine
- Pediatric Cardiology
- Respiratory Medicine
Background:
- Extremely low gestational age newborns (ELGANs) are a highly vulnerable population.
- Bronchopulmonary dysplasia (BPD) is a common complication in ELGANs, often associated with pulmonary hypertension (BPD-PH).
- Understanding the incidence and management of BPD-PH in the most immature infants is critical.
Purpose of the Study:
- To determine the incidence and severity of BPD-PH in extremely immature ELGANs (230/6-256/7 weeks gestational age).
- To assess the efficacy of pharmacologic treatment for BPD-PH in this population.
Main Methods:
- Prospective observational cohort study.
- Echocardiography markers and serum NT-proBNP levels were used to assess BPD-PH at 3 and 12 months chronological age.
- Incidence and efficacy of pharmacologic treatment were analyzed.
Main Results:
- At 3 months, 44% (15/34) of ELGANs showed echocardiographic evidence of BPD-PH.
- At 12 months, 6/34 infants still had pulmonary hypertension.
- PH-targeted therapy, including sildenafil and dual oral combination therapy, was administered to all affected infants.
Conclusions:
- Nearly half of extremely immature ELGANs develop BPD-PH.
- Pharmacotherapy led to hemodynamic improvements in most infants by 12 months of age.
- Early intervention with PH-targeted therapy is effective in managing BPD-PH in ELGANs.
Objective:
Extremely low gestational age newborns (ELGANs) represent an especially vulnerable population. Herein, we aimed to determine incidence and severity of pulmonary hypertension associated with bronchopulmonary dysplasia (BPD-PH) in extremely immature ELGANs (gestational age: 230/6-256/7 weeks).
Methods:
In this prospective observational cohort study, we assessed BPD-PH by means of several echocardiography markers and serum N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels at 3 and 12 months of chronological age. In addition, we analyzed incidence and efficacy of pharmacologic treatment for BPD-PH.
Results:
At 3 months 15/34 ELGANs had echocardiographic evidence of BPD-PH, while at 12 months of age 6/34 still had PH. PH-targeted therapy consisted of sildenafil monotherapy in 11 and dual oral combination therapy (sildenafil and macitentan) in four ELGANs at 3 and 12 months.
Conclusion:
44% (15/34) of ELGANs developed BPD-PH. All received PH-targeted pharmacotherapy at 3 months, leading to hemodynamic improvements at 12 months in most infants.
Related Concept Videos
Pulmonary Hypertension: Classification and Pathogenesis
There are various classifications for PH, each relating to different underlying causes and also...
Pulmonary Embolism I: Introduction
Mitral Valve Prolapse III: Nursing Management
Pneumothorax-I
Pneumothorax can be even further classified as spontaneous, traumatic, and tension pneumothorax.
Pulmonary Cycle: Exhalation
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care

